Literature DB >> 9205173

Is there an advantage to repairing infected mitral valves?

D D Muehrcke1, D M Cosgrove, B W Lytle, P C Taylor, A M Burgar, C P Durnwald, F D Loop.   

Abstract

BACKGROUND: The therapy for native mitral valve endocarditis is in evolution. Antibiotics have significantly improved survival rates, but patients with complications of endocarditis may require surgical treatment.
METHODS: Between January 1985 and December 1995, 146 patients underwent surgical therapy (repair or replacement) for native mitral valve endocarditis. All patients had documented bacterial endocarditis. Univariate and multivariate analyses were performed to determine predictors of hospital death, long-term event-free survival, and probability of repair. Patients were evaluated in three groups: all patients, patients with acute endocarditis, and patients with chronic endocarditis.
RESULTS: There were ten hospital deaths (6.8%). Patients undergoing repair had a lower hospital mortality rate (p = 0.008) then those having replacement. Event-free survival was improved after mitral valve repair in the overall group (p = 0.02) and in the group with healed (chronic) endocarditis (p = 0.05). Although the acute endocarditis group demonstrated an improved event-free survival rate after mitral valve repair versus replacement (74% versus 20% at 6 years), this did not reach statistical significance.
CONCLUSIONS: We conclude that mitral valve repair is preferable to mitral valve replacement when possible, in patients with complications of endocarditis, as repair results in a lower hospital mortality and an improved long-term survival.

Entities:  

Mesh:

Year:  1997        PMID: 9205173     DOI: 10.1016/s0003-4975(97)00271-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  15 in total

1.  Mitral valve reconstruction in the presence of infection.

Authors:  S A Livesey
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

Review 2.  Surgical reconstruction of the mitral valve.

Authors:  S M Tuladhar; P P Punjabi
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

3.  Long term results of mechanical prostheses for treatment of active infective endocarditis.

Authors:  J M Guerra; M P Tornos; G Permanyer-Miralda; B Almirante; M Murtra; J Soler-Soler
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

4.  Combined aortic and mitral valve repair in active infective endocarditis.

Authors:  Hiroichiro Yamaguchi; Kiyoyuki Eishi; Shiro Yamachika; Kazuyoshi Tanigawa; Kenta Izumi; Seiji Matsukuma
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-07

5.  Infective endocarditis in Europe: lessons from the Euro heart survey.

Authors:  P Tornos; B Iung; G Permanyer-Miralda; G Baron; F Delahaye; Ch Gohlke-Bärwolf; E G Butchart; P Ravaud; A Vahanian
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

6.  Mitral valve repair for active culture positive infective endocarditis.

Authors:  G Doukas; M Oc; C Alexiou; A W Sosnowski; N J Samani; T J Spyt
Journal:  Heart       Date:  2005-06-10       Impact factor: 5.994

7.  Outcome of surgical management for active mitral native valve infective endocarditis: a collective review of 57 patients.

Authors:  Takashi Miura; Masayoshi Hamawaki; Shiro Hazama; Koji Hashizume; Tsuneo Ariyoshi; Mizuki Sumi; Akitsugu Furumoto; Nobuo Saito; Akira Tsuneto; Kiyoyuki Eishi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-02-13

8.  Mitral valve repair for infective endocarditis.

Authors:  Tadashi Omoto; Masahiro Ohno; Masaomi Fukuzumi; Masaya Ohi; Takahisa Okayama; Noboru Ishikawa; Hitoshi Kasegawa; Takeo Tedoriya
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-06-18

Review 9.  Mitral valve repair versus replacement.

Authors:  Stephanie L Mick; Suresh Keshavamurthy; A Marc Gillinov
Journal:  Ann Cardiothorac Surg       Date:  2015-05

10.  Fulminant Infective Endocarditis Due to Kingella Kingae and Several Complications in a 6-Year-Old Girl: A Case Report.

Authors:  Raphael Joye; Dimitri Ceroni; Maurice Beghetti; Yacine Aggoun; Tornike Sologashvili
Journal:  Front Pediatr       Date:  2021-07-05       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.